These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27404671)

  • 1. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.
    Kourlaba G; Gialama F; Tsioufis K; Maniadakis N
    Int J Cardiol; 2016 Oct; 221():60-74. PubMed ID: 27404671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The repercussion of stopping reimbursement of olmésartan on antihypertensive drugs prescription and blood pressure control of treated hypertensive patients in France.
    Dufay A; Gallo A; Hanon O; Vaïsse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2018 Jun; 67(3):149-153. PubMed ID: 29807620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of published economic evaluations of angiotensin receptor blockers.
    Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
    Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
    Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
    Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
    Rump LC; Sellin L
    Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.
    Ren M; Xuan D; Lu Y; Fu Y; Xuan J
    J Med Econ; 2020 Apr; 23(4):394-400. PubMed ID: 31782677
    [No Abstract]   [Full Text] [Related]  

  • 18. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
    Smith DH
    Am J Cardiovasc Drugs; 2007; 7(5):347-56. PubMed ID: 17953473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].
    Belén Ferro-Rey M; Roca-Cusachs A; Sicras-Mainar A; Alvarez-Martín C; de Salas-Cansado M
    Aten Primaria; 2011 Jul; 43(7):345-55. PubMed ID: 21216500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.